<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; monoclonal antibody</title>
	<atom:link href="http://oralcancernews.org/wp/tag/monoclonal-antibody/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 21 May 2012 12:57:26 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Roche scientist provides a look at drugmaker&#8217;s early pipeline</title>
		<link>http://oralcancernews.org/wp/roche-scientist-provides-a-look-at-drugmakers-early-pipeline/</link>
		<comments>http://oralcancernews.org/wp/roche-scientist-provides-a-look-at-drugmakers-early-pipeline/#comments</comments>
		<pubDate>Mon, 02 Jan 2012 13:41:44 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[enzymes]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[genes]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[mutation]]></category>
		<category><![CDATA[personalized medicine]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12248</guid>
		<description><![CDATA[Source: www.nj.com/ Author: Susan Todd/The Star-Ledger Jean-Jacques Garaud, who heads Roche’s pharmaceutical research and early development efforts in Switzerland, visited the drugmaker’s Nutley campus in mid-December and spent some time speaking with The Star-Ledger about the company’s efforts in the laboratory. The talk with Garaud provided a rare glimpse of the giant Swiss drugmaker’s early-stage [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/roche-scientist-provides-a-look-at-drugmakers-early-pipeline/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US FDA approval for expanded use of Erbitux</title>
		<link>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/</link>
		<comments>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:24:41 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-fluorouracil]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[infusion]]></category>
		<category><![CDATA[monoclonal antibody]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12055</guid>
		<description><![CDATA[Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Non-platinum regimen works in head, neck cancer</title>
		<link>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:32:19 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[alimta]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[pemetrexed]]></category>
		<category><![CDATA[vascular epithelial growth factor]]></category>
		<category><![CDATA[VEGF]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8806</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Antibody improves head and neck cancer results</title>
		<link>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/</link>
		<comments>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:24:13 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epidermal growth factor receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[nimotuzumab]]></category>
		<category><![CDATA[toxicity]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8800</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel antibody improved outcomes for patients with advanced and inoperable squamous cell carcinoma of the head and neck, researchers reported. Combined with radiation or chemoradiation, the substance &#8212; a fully humanized monoclonal antibody dubbed nimotuzumab &#8212; significantly outperformed either modality alone in an open-label [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-antibody-improves-head-and-neck-cancer-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Presence of rash associated with improved survival in patients receiving adjuvant Erbitux® for locally advanced head and neck cancer</title>
		<link>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 18 Nov 2009 02:52:02 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[epithelial growth factory receptor]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=7393</guid>
		<description><![CDATA[Source: professional.cancerconsultants.com Author: staff A multicenter randomized trial has shown that patients with locoregionally advanced head and neck cancer receiving adjuvant Erbitux® (cetuximab) and radiotherapy who develop a rash have a better survival than patients receiving this therapy who don’t develop a rash. The details of this five-year follow-up of a Phase III randomized study [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/presence-of-rash-associated-with-improved-survival-in-patients-receiving-adjuvant-erbitux%c2%ae-for-locally-advanced-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Treatment approach using radiofrequency waves heats up</title>
		<link>http://oralcancernews.org/wp/treatment-approach-using-radiofrequency-waves-heats-up/</link>
		<comments>http://oralcancernews.org/wp/treatment-approach-using-radiofrequency-waves-heats-up/#comments</comments>
		<pubDate>Wed, 25 Mar 2009 15:41:09 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[gold nanoparticles]]></category>
		<category><![CDATA[M.D. Anderson Cancer Center]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[radiofrequency]]></category>
		<category><![CDATA[RF]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=2220</guid>
		<description><![CDATA[Source: www.cancer.gov/ncicancerbulletin Author: Carmen Phillips It began with chemotherapy-induced sleeplessness and some pie pans. At one point hot dogs were involved. It inspired residents of two small communities 1,300 miles apart, and eventually landed in the labs of two major academic medical centers. And, sadly, just 5 weeks ago, the man who began it all [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/treatment-approach-using-radiofrequency-waves-heats-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

